Table 5.

Studies included in the systematic review.

MicroRNA	Biofluid Type	Deregulation	Reference
miRNA-27a	Serum	↑ BC vs. C	[32]
	Plasma	↑ BC vs. C	[33]
		↑ Late BC vs. early BC
		=Benign vs. C vs. high risk BC
		=high risk BC vs. C
	Plasma	↑ BC vs. C	[34]
	Serum	↑ Primary BC vs. benign breast lesions	[35]
		↑ Primary BC vs. C
		↑ Benign breast lesions vs. C
	Plasma	↑ BC vs. C	[36]
		↓ BC after chemotherapy vs. BC before chemotherapy
		↑ BC after chemotherapy vs. C
	Serum	↓ BC vs. C	[37]
	Plasma	↓ BC vs. C	[38]
	Serum	↑ BC vs. C	[39]
	Plasma	↑ BC vs. C	[40]
miRNA-128	Plasma	↓ BC vs. high-risk BC	[41]
	Serum	=BC vs. C	[42]

BC, Breast Cancer. C, healthy controls.